– Novavax is on target to make over $475 million in sales this year, and by the end of the year, it will be distributing two separate vaccines and generating more than $4 billion in annual revenue.
– Whenever the company’s NanoFlu product for seasonal influenza in older adults hits the market, it’s predicted to be a massive success.
Novavax Inc(NVAX) is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about NVAX. We will be studying the movement so you can make the best decision as an investor. The stock has moved downwards today by 0.84%. The high for today is 191.00 and today’s low is 182.44. This information is critical in deciding whether this investment is risky or not. We can see the stock is trending downwards, which means the volume of people selling this stock is greater than people buying it.
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
As an investor, you can get an idea of where the stock is trending by the forecast. In this case, the high forecast for Novavax Inc is $400.00 and the low forecast is $317.00. We can get a look into the future by looking at past trends. Looking at Novavax Inc’s 5-year movement it seems it has grown 68%. Overall, Novavax Inc is in great shape going forward. They have a strong market cap of $13.61B and a very bright future ahead of them.